Press Releases

Title	Date
SATELLOS Announces Proposed Non-Brokered Offerings Of Unsecured Non-Convertible Debentures of up to $2.25 Million	March 19, 2023
SATELLOS to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit	March 19, 2023
SATELLOS Announces Further Preclinical Progress with Development Candidate	March 10, 2023
SATELLOS Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model	February 6, 2023
SATELLOS Announces Development Candidate	January 3, 2023
SATELLOS Announces Q3 2022 Financial Results and Operational Highlights	November 23, 2022
SATELLOS Announces Advancement of Compounds to Next Stage of Development	November 3, 2022
SATELLOS to present preliminary preclinical proof of concept data for an additional rare disease at World Muscle Society Meeting	October 11, 2022
SATELLOS INC. Announces Licensing of Formulation Technology and Expand Collaboration with NW PHARMATECH LTD.	October 6, 2022
SATELLOS Announces OTCQB Listing in the United States	October 6, 2022
SATELLOS Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer	September 28, 2022
SATELLOS Announces Closing of Offering of Units	September 13, 2022
SATELLOS Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units	September 7, 2022
SATELLOS Announces Pricing of Proposed Offering of Units	August 31, 2022
SATELLOS Reports Q2 2022 Financials and Operating Results	August 29, 2022
SATELLOS Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units	August 29, 2022
SATELLOS Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications	July 13, 2022
SATELLOS Announces Proposed Offering of Units	July 11, 2022
SATELLOS Announces In-Licensing of New Patent Application	June 30, 2022
SATELLOS Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society	June 22, 2022
SATELLOS Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 Grant	June 17, 2022
SATELLOS to present at Bio International Convention 2022	June 14, 2022
SATELLOS to Present at the LD Micro Invitational	June 1, 2022
SATELLOS Announces Q1 2022 Results and Operational Highlights	May 31, 2022
SATELLOS Announces 2021 Year End Financial Results and Operational Highlights	May 2, 2022
SATELLOS to Present at the 2022 Bloom Burton & CO. Healthcare Investor Conference 2022	April 26, 2022
SATELLOS to Present at Upcoming European Molecular Biology Organization Workshop	April 21, 2022
SATELLOS to Present at Upcoming Game Changing Science During March 30 Drug Discovery News Webinar	March 29, 2022
SATELLOS Provides Update on Novel Regenerative Drug Candidates	March 15, 2022
SATELLOS Provides Update on Joint Development Initiative with NW PharmaTech Limited	March 11, 2022
SATELLOS to Present Game Changing Science at Insights In Research Investor Summit and MDA Clinical & Scientific Conference 2022	March 10, 2022
SATELLOS to Participate at BIO CEO & Investor Conference 2022	February 10, 2022
Shareholder Letter from CEO	January 24, 2022
SATELLOS to participate at BIOTECH SHOWCASE™ Virtual 2022	January 10, 2022
SATELLOS Announces Research Agreement with Université De Sherbrooke to Study Rare Muscular Dystrophies	December 16, 2021
SATELLOS Announces New Board Appointments	December 6, 2021
SATELLOS Reports Third Quarter 2021 Financial Results and Operational Highlights	November 29, 2021
SATELLOS Retains BND Projects Inc. for Strategic Investor Relations Services	October 26, 2021
SATELLOS Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration	September 17, 2021
SATELLOS Announces Evidence for Regeneration in Severe Model of Duchenne	September 13, 2021
SATELLOS Announces Second Quarter 2021 Financial Results and MD&A	August 30, 2021
SATELLOS Announces High Resolution Crystal Structure of Duchenne Drug Target	August 26, 2021
SATELLOS Announces Partnership with Jesse’s Journey	August 25, 2021
SATELLOS Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBD	August 18, 2021
SATELLOS and iCo Announce Completion of Reverse Takeover	August 13, 2021
iCo Therapeutics Inc. Announces Shareholder Approval of business combination with Satellos Bioscience Inc.	August 5, 2021
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update regarding Business Combination with Satellos Bioscience Inc.	July 8, 2021
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting	May 10, 2021
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan Koppy	April 29, 2021
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private Placement	April 27, 2021
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private Placement	April 22, 2021
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.	March 22, 2021
iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2	March 15, 2021
iCo Therapeutics Inc. Announces Warrant Exercises	March 11, 2021
iCo Therapeutics Inc. Proposes to Re-Price Warrants	January 11, 2021
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical	December 31, 2020
iCo Therapeutics Announces Third Quarter 2020 Financial Results	November 24, 2020
iCo Therapeutics Announces Option Grants	October 26, 2020
iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020	October 21, 2020
iCo Therapeutics Announces Second Quarter 2020 Financial Results	August 31, 2020
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal	July 30, 2020